Bristol Myers Squibb (BMY) Receivables - Other (2009 - 2026)

Bristol Myers Squibb has disclosed Receivables - Other across 18 years of filings, most recently posting $149.0 million for Q1 2026.

• In Q1 2026, Receivables - Other fell 91.43% year-over-year to $149.0 million; the TTM figure through Mar 2026 stood at $149.0 million (down 91.43% YoY), while the FY2025 annual figure was $1.8 billion, up 372.99% from the prior year.
• Receivables - Other declined to $149.0 million in Q1 2026, from $1.8 billion in the prior quarter.
• Over the last five years, Receivables - Other for BMY reached as high as $1.8 billion in Q4 2025 and fell as low as $149.0 million in Q1 2026.
• The 5-year median for Receivables - Other is $410.0 million (2022), against an average of $616.5 million.
• Annual changes were most pronounced in 2025 — Receivables - Other jumped 372.99% — and 2026, when it sank 91.43%.
• A 5-year view of Receivables - Other shows it stood at $504.0 million in 2022, then dropped by 17.46% to $416.0 million in 2023, then fell by 7.45% to $385.0 million in 2024, then jumped by 372.99% to $1.8 billion in 2025, then sank by 91.82% to $149.0 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $149.0 million, $1.8 billion, and $224.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.